Abstract Brain phospholipids are highly enriched in docosahexaenoic acid (DHA; 22:6n-3). Recent advances indicate that 22:6n-3 is released from brain phospholipids via the action of phospholipase A 2 (PLA 2 ) in response to several stimuli, including neurotransmission, where it then acts as a secondary messenger. Furthermore, it is now known that released 22:6n-3 is a substrate for several oxygenation enzymes whose products are potent signaling molecules. One emerging candidate PLA 2 involved in the release of 22:6n-3 from brain phospholipids is the group VI calciumindependent phospholipase A 2 (iPLA 2 ). After a brief review of brain 22:6n-3 metabolism, cell culture and rodent studies facilitating the hypothesis that group VI iPLA 2 releases 22:6n-3 from brain phospholipids are discussed. The identification of PLA 2 s involved in cleaving 22:6n-3 from brain phospholipids could lead to the development of novel therapeutics for brain disorders in which 22:6n-3 signaling is disordered.-Green, J. T., S. K. Orr, and R. P. Bazinet. The emerging role of group VI calcium-independent phospholipase A 2 in releasing docosahexaenoic acid from brain phospholipids. J. Lipid Res. 2008. 49: 939-944. 
of neurological disorders, including stroke (13) , Alzheimer's disease (14) , and major depression (15) .
The brain cannot synthesize n-3 PUFAs de novo; therefore, it must either take up preformed 22:6n-3 or desaturate and elongate one of its precursors. With regard to the latter, although brain cells and in particular astrocytes have the capacity to desaturate and elongate a-linolenic acid (18:3n-3) to 22:6n-3 (16) , in vivo tracer studies suggest that brain desaturation/elongation is a relatively minor pathway (0.024 pmol/g brain/s) (17) compared with brain uptake of preformed 22:6n-3 (13-15 pmol/g brain/s) (17) (18) (19) . Furthermore, unlike the liver, the brain does not upregulate its ability to desaturate and elongate 18:3n-3 to 22:6n-3 when dietary n-3 PUFAs are limited (20) (21) (22) .
Plasma unesterified 22:6n-3 rapidly disassociates from albumin, passes through the blood-brain barrier, and enters the brain (Fig. 1, step A) (23) (24) (25) . Upon its entry, 22:6n-3 is activated by an acyl-CoA synthetase (26, 27) . A small portion of the newly formed docosahexaenoyl-CoA is b-oxidized (28, 29) , and the remainder is esterified via an acyl-CoA transferase to the sn-2 position of phospholipids. The 22:6n-3 that enters the brain and passes through the docosahexaenoyl-CoA pool is esterified into brain phospholipids at a rate of 13-15 pmol/g brain/s. This 22:6n-3 pool is predominantly esterified to ethanolamine (6-7 pmol/g brain/s) and choline glycerophospholipids (4-5 pmol/g brain/s) (28) (29) (30) (31) , and subsequent remodeling and de novo phospholipid synthesis likely explain its relative mass distribution within various phospholipid species (32). Phospholipid 22:6n-3 (sn-2 esterified) is then released by phospholipase A 2 (PLA 2 ) at a net rate of 102-131 pmol/g brain/s (29) (30) (31) . A portion of the released 22:6n-3 is available for the synthesis of oxygen-ated derivatives via cyclooxygenase-2 (33) or a putative 15-lipoxygenase (34) , whereas the remainder is activated by an acyl-CoA synthetase in which, again, a small portion of it is available for b-oxidation and the remainder is reesterified into the sn-2 position of brain phospholipids. Kinetic studies estimate that under basal conditions, ?90% of the 22:6n-3 that is released via PLA 2 is reesterified into the sn-2 position of brain phospholipids (29) (30) (31) , and the Fig. 1 . Docosahexaenoic acid (DHA; 22:6n-3) rapidly disassociates from plasma albumin and passes through the blood-brain barrier (A) into the brain, where it is activated by an acyl-CoA synthetase (B). Upon its activation, a small proportion of 22:6n-3 can be b-oxidized (C), whereas the remainder is esterified to a 2-lysophospholipid via acyl-CoA transferase (D). In this model, group VI calcium-independent phospholipase A 2 (iPLA 2 ) releases 22:6n-3 from neural phospholipids (creating the 2-lysophospholipid) (E), where a portion can be converted to oxygenated derivatives (F) or activated by acyl-CoA synthetase (G). ATP, thrombin, and bradykinin are known activators of iPLA 2 . Although cholinergic (M1) and serotonergic (5-HT2A) receptor activation releases 22:6n-3 from neural phospholipids, the PLA 2 isoform involved is not known. Plasma unesterified 22:6n-3 enters the brain and is esterified to a 2-lysophospholipid at a rate of 13-15 pmol/g brain/s. However, the net rate of 22:6n-3 esterification to brain phospholipids also includes recycled 22:6n-3, leading to a net rate of 22:6n-3 entry into phospholipids from the docosahexaenoyl-CoA pool (D) of 102-131 pmol/g brain/s, which at steady state approximates the rate of 22:6n-3 release from brain phospholipids (E). NPD1, neuroprotectin D1; RvD1, resolvin D1.
10% that is lost is replaced by uptake from the plasma unesterified 22:6n-3 pool (35).
BRAIN PLA 2
To date, at least 22 genes that encode PLA 2 proteins have been identified in mammals. PLA 2 s cleave fatty acids from the sn-2 position of glycerophospholipids, resulting in an unesterified "free fatty acid" and a 2-lysophospholipid. On a broad level, the mammalian PLA 2 isoforms differ with respect to their tissue and cellular distribution, substrate specificities, and calcium requirements, and interested readers should consult other reviews for more details (36) (37) (38) (39) (40) (41) , including PLA 2 nomenclature/classification (41, 42) . The isoforms identified in the brain to date include groups IVA, IVB, and IVC calcium-dependent cytosolic phospholipase A 2 (cPLA 2 ), groups IIA, IIC, IIE, V, and X calcium-dependent secretory phospholipase A 2 (sPLA 2 ), and groups VIA and VIB calcium-independent phospholipase A 2 (iPLA 2 ) (43) (44) (45) (46) (47) (48) (49) . It is worth noting that the mouse strains C57BL/6, 129/Sv, and B10.RIII have a naturally occurring missense mutation in the gene encoding for the group IIA sPLA 2 (45, (50) (51) (52) . As new proteins with PLA 2 -like activity are identified (53, 54) and specific antibodies and reagents are developed, it is possible that more isoforms will be detected within the brain. Another, yet to be cloned, PLA 2 whose activity has been detected in the brain is the plasmalogen-selective PLA 2 (55) . This enzyme is capable of cleaving fatty acids from plasmanylethanolamine, and because in the brain this glycerophospholipid is rich in 22:6n-3, it is possible that this enzyme may also play a role in 22:6n-3 release from brain phospholipids (39, 56) . GROUP VI iPLA 2 : OVERVIEW There are two distinct members of the iPLA 2 family, group VIA iPLA 2 and group VIB iPLA 2 . The 85-88 kDa group VIA iPLA 2 was first isolated from macrophages in 1994 (57) and independently cloned by two laboratories in 1997 (58, 59) , whereas the group VIB iPLA 2 was cloned in 2000 (49) . The group VIA iPLA 2 shares several conserved regions at the C terminus but has very little homology at the N terminus with the group VIB iPLA 2 . The group VI iPLA 2 s do not require calcium for their activity but do use ATP for stabilization; they are stimulated by thrombin and bradykinin (40, 60) but inhibited by bromoenolactone (61). However, very little is known about the molecular/genetic regulation of group VI iPLA 2 , especially within the brain (62) . Initial studies suggested a homeostatic role for group VI iPLA 2 in regulating membrane turnover (for review, see Ref. 63) . However, several studies have now shown that group VI iPLA 2 plays an important role in signal transduction (for review, see Refs. 40, 64) .
In the brain, the basal expression and activity of group VI iPLA 2 is higher than that of other PLA 2 s (43, 65-67) and its protein expression decreases during aging (68) . Whereas brain cPLA 2 and sPLA 2 are commonly thought to be selective for arachidonic acid (20:4n-6) release (64, (69) (70) (71) (72) (73) , the specific activity of group VI iPLA 2 using 1-palmitoyl 2-R-phosphatidylcholine when linoleic acid (18:2n-6), palmitic acid, oleic acid, or 20:4n-6 were esterified in the sn-2 position (R) was 10.0, 4.3, 3.0, and 2.0 mmol/min/mg protein, respectively (65) . However, it is important to consider cellular localization and substrate availability when trying to determine in vivo selectivity. The net rate of release of 18:2n-6 from brain phospholipids (19 pmol/g brain/s) was at least five times lower than that of 22:6n-3 (102-131 pmol/g brain/s), and when preformed 22:6n-3 is present in chow, the concentration of phospholipid esterified 18:2n-6 (987 nmol/g brain) was almost 15 times lower than that of 22:6n-3 (13,844 nmol/g brain) (18) . Although these latter observations do not suggest that group VI iPLA 2 is not involved in cleaving 18:2n-6 from brain phospholipids, they do raise the question of why so much group VI iPLA 2 is present in the brain when so little 18:2n-6 is present.
GROUP VI iPLA 2 AND 22:6n-3 RELEASE FROM BRAIN PHOSPHOLIPIDS
Evidence from cell culture studies The first suggestion that brain group VI iPLA 2 may be selective for 22:6n-3 release came from Strokin, Sergeeva, and Reiser (60) when they observed that bromoenolactone inhibited 22:6n-3 but not 20:4n-6 release from phospholipids of astrocytes stimulated with ATP. This study was followed up by showing that bromoenolactone also inhibited oxygen/glucose deprivation-induced 22:6n-3 release from hippocampal phospholipids (74) . In 2007, Strokin, Sergeeva, and Reiser (48) repeated their 2003 finding in which ATP-stimulated 22:6n-3 release from astrocyte phospholipids was inhibited with bromoenolactone and reproduced this effect with small interfering RNA silencing of group VIB iPLA 2 . This latter study addressed the issue of bromoenolactone inhibition selectivity and was followed up by further demonstrating that bromoenolactone inhibition of 22:6n-3 release from astrocyte phospholipids was absent upon silencing group VIB iPLA 2 .
Evidence from in vivo studies
DeMar et al. (75) tested the half-life of [4, H]22:6n-3 upon its intracerebroventricular administration to rats that had consumed a diet either adequate or deprived of n-3 PUFAs for 15 weeks postweaning. The half-life of [4, H]22:6n-3 in brain phospholipids of rats consuming the n-3 PUFA-adequate diet was 33 days, whereas it was increased to 90 days in the deprived rats. This conservation of [4,5- 3 H]22:6n-3 suggested that enzymes involved in the catabolism of 22:6n-3 must be downregulated in the brains of n-3 PUFA-deprived rats, and in a subsequent experiment candidate brain PLA 2 isoforms (IIA sPLA 2 , IVA cPLA 2 , and VIA iPLA 2 ) were examined (47) . Whereas the activity, protein, and mRNA of group IVA cPLA 2 and group IIA sPLA 2 were upregulated in the brains of rats iPLA 2 releases docosahexaenoic acidconsuming the n-3 PUFA-deprived diet, only the group VIA iPLA 2 (47, 75) . The activity, protein, and mRNA of group VIA iPLA 2 were downregulated; however, the mechanism by which group VIA iPLA 2 mRNA was downregulated was not explored, and whether or not there was a downregulation of group VIB iPLA 2 was not tested.
CONSEQUENCES OF 22:6n-3 RELEASE FROM BRAIN PHOSPHOLIPIDS
Although many important functions have been attributed to 22:6n-3 within the brain (2, (76) (77) (78) , few studies have attempted to test whether these functions are related to released 22:6n-3. Rats deprived of dietary n-3 PUFAs to reduce brain concentrations have behavioral deficits (79, 80) , altered neurotransmission (81, 82) , decreased iPLA 2 activity and expression (47) , and decreased 22:6n-3 release from brain phospholipids (75, 83) . A portion of released 22: 6n-3 can be converted to neuroprotectin D1 or resolvin D1 (Fig. 1, step F) , two signaling molecules involved in brain cell survival and the resolution of inflammation (10, 13, 84) . Docosahexaenoyl-CoA is a hepatic nuclear factor-4a ligand (85), whereas unesterified 22:6n-3 is a peroxisome proliferator-activated receptor ligand (86) . Unesterified 22:6n-3 inhibits protein kinase C activity (87) and has been implicated in the regulation of brain nuclear factor-kB (13), p38 mitogen-activated protein kinase (5), Bcl-2 (84), and Akt (88) 
SUMMARY AND CONCLUSIONS
Recent studies have identified 22:6n-3 as an important secondary messenger within the brain. The PLA 2 isoform involved in 22:6n-3 release from neural phospholipids upon cholinergic (M1) (6, 8) and serotonergic (5-HT2A) (7, 92) stimulation is not known. Unesterified 22:6n-3 likely directly, as well as through its oxygenated derivatives, participates in signal transduction. Cell culture studies using small molecule inhibitors and small interfering RNAs as well as kinetic studies in the rodent brain suggest that group VI iPLA 2 is involved in cleaving 22:6n-3 from brain phospholipids (Fig. 1) . Future studies are needed to identify the specific roles of group VIA and VIB iPLA 2 in 22:6n-3 release from brain phospholipids. Further approaches to answering these questions could include the study of sn-2 radiolabeled 22:6n-3 glycerophospholipids in group VI iPLA 2 -specific assay systems, the generation and characterization of groups VIA and VIB iPLA 2 brain-specific knockouts, or the assessment of 22:6n-3 kinetics in other models with altered brain group VI iPLA 2 activity. To date, it is known that group VIA iPLA 2 decreases in the hippocampus in response to aging (68) and in the cortex in response to dietary n-3 PUFA deprivation (47) . Whether or not decreased group VI iPLA 2 and its potential ability to regulate 22:6n-3 release from brain phospholipids are contributing factors in the susceptibility of the aged or the n-3 PUFA-deprived brain to disease remains to be tested.
